In this issue:
Global patterns and trends in breast cancer incidence and mortality
Sequential ADC use in HER2-low metastatic breast cancer
Imlunestrant ± abemaciclib in advanced breast cancer
Adjuvant atezolizumab for early triplenegative breast cancer
Nivolumab timing with neoadjuvant carboplatin and paclitaxel for triple-negative breast cancer
TILs and survival outcomes in HER2-positive breast cancer
Concurrent conditions and medications: impact on neoadjuvant chemotherapy response in breast cancer
TROP2 ADC for HER2-negative metastatic breast cancer with brain metastases
PROs with trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer
Pertuzumab retreatment for HER2-positive locally advanced/metastatic breast cancer
Please login below to download this issue (PDF)